ClinicalTrials.gg
CompletedNCT03296787Updated Aug 25, 2020Results posted

A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954

A Phase 1 interventional study of TAK-954 in Renal Impairment and Healthy Volunteers, sponsored by Takeda. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-25.

Sponsored by Takeda · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Renal Insufficiency by Takeda — 1 open to participants now, 1 under way, none of them phase 3. Renal Insufficiency · Takeda.

Enrollment
8th of 11
32 · median 48
Started
2017
the only one that year
Phase 1
7 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Renal Insufficiency by Takeda, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 1, and was the 8th registered.

Renal Insufficiency

1,414 studies on the registry are indexed under Renal Insufficiency; 147 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 12 studies in Renal Insufficiency by Takeda is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Renal Insufficiency by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of varying degrees of renal function on the PK of TAK-954 following single-dose IV administration and to investigate the impact of hemodialysis on the PK of single IV doses of TAK-954.

Read the detailed description

The drug being tested in this study is called TAK-954. This study will evaluate the effect of varying degrees of renal function on the PK of TAK-954 following single-dose IV administration and to investigate the impact of hemodialysis on the PK of single IV doses of TAK-954.

The study will enroll approximately up to 40 participants. Participants will be enrolled in one of the 5 treatment groups based on their renal impairment which will be determined based on Cockcroft and Gault (CG) equation as follows:

  • Group A TAK-954 0.2 mg: Healthy Participants
  • Group B TAK-954 0.2 mg: Mild Renal Impairment
  • Group C TAK-954 0.2 mg: Moderate Renal Impairment
  • Group D TAK-954 0.2 mg: Severe Renal Impairment or End-stage Renal Disease (ESRD) Without Hemodialysis
  • Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD) With Hemodialysis

All participants in groups A to D will receive a single dose of TAK-954 and two single doses in Group E.

Enrollment in Group B (Mild) and Group E (ESRD requiring dialysis) will be based on assessment of safety and available PK data from Group C and Group D respectively.

This multi-center trial will be conducted in Czech Republic and Hungary. The overall time to participate in this study is approximately 8 weeks. Participants in Groups A to D will remain confined to clinic for 3 days. For both treatments, participants in Group E requiring dialysis will remain confined to clinic for 3 days. All participants will make a final visit to the clinic 10-14 days after receiving their last dose for a follow-up assessment.

03

Conditions studied

  • Renal Impairment
  • Healthy Volunteers

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All participants: Male and female participants (non-) who are aged 18 to 75 years, inclusive, with a (BMI) between 18 to 35 kilogram per square meter (kg/m\^2).
  2. Group A: As much as possible, the healthy participants with normal renal function ( [CLcr] greater than or equal to [>=] 90 milliliter per minute [mL/min]) should be comparable to participants with renal impairment with respect to median age and weight (approximately 50 percent [%] of healthy participants on each side of the median age and weight of currently enrolled renally-impaired participants grouped together), sex, and race. This will be decided by the investigators in discussion with Takeda.
  3. Groups B to E: Participants who have stable RI, defined as no change in disease status, as documented by the participant's most recent CLcr assessment; serum creatinine must not vary more than approximately 30% from Screening to Day -1 to confirm stable disease. Participants should also be in good health commensurate with their renal status.

    • Group B: Participants with mild RI (CLcr 60 to less than [\<] 90 mL/min).
    • Group C: Participants with moderate RI (CLcr 30 to \<60 mL/min).
    • Group D: Participants with severe RI or ESRD but not requiring dialysis (CLcr \<30 mL/min).
    • Group E: Participants with ESRD requiring dialysis (\<15 mL/min requiring hemodialysis at least 3 times/week, and having been on the same dialysis treatment regimen for at least 1 month before trial entry).
  4. Participants should be on a stable drug regimen defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) before dosing with TAK-954.

Exclusion criteria

Exclusion Criteria:

  1. All participants:

    • Are renal allograft recipients within 1 year of screening.
    • Have a history of gastrointestinal (GI) motility disorder or intestinal obstruction.
    • Have urinary incontinence without catheterization.
  2. Group A: Participants who, in the discretion of the investigator, have a history of endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases will be excluded from the trial.
  3. Groups B to E:

    • Receive dialysis other than intermittent dialysis (except Group E).
    • Have renal disease secondary to hepatic disease (hepatorenal syndrome).
    • At the discretion of the investigators, have any significant hepatic, cardiac, or pulmonary disease or participants who are clinically nephrotic.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Group A TAK-954 0.2 mg: Healthy Participants

    Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.

    Drug: TAK-954

  • Experimental
    Group B TAK-954 0.2 mg: Mild Renal Impairment

    Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.

    Drug: TAK-954

  • Experimental
    Group C TAK-954 0.2 mg: Moderate Renal Impairment

    Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.

    Drug: TAK-954

  • Experimental
    Group D TAK-954 0.2 mg: Severe Renal Impairment

    Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.

    Drug: TAK-954

  • Experimental
    Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)

    Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.

    Drug: TAK-954

Interventions

06

What researchers measure

Primary outcomes

  1. Groups A, C and D; Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free)

    Time frame: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion

  2. Groups A, C and D; AUC(0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Post-dose for TAK-954 (Free and Total)

    Time frame: Day 1 pre-infusion and at multiple time points (up to 72 hours) post-infusion

  3. Groups A, C and D; AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 (Free and Total)

    Time frame: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion

  4. Groups A, C and D; AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 (Free and Total)

    Time frame: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion

  5. Groups A, C and D; Ae: Amount of TAK-954 Excreted in Urine

    Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion

  6. Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 1

    Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion

  7. Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 2

    Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion

  8. Groups A, C and D; Fe: Fraction of TAK-954 Excreted in Urine

    Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion

  9. Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 1

    Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion

  10. Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 2

    Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion

  11. Groups A, C and D; CLR: Renal Clearance for TAK-954

    Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion

  12. Group E; CLR: Renal Clearance for TAK-954 in Period 1

    Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion

  13. Group E; CLR: Renal Clearance for TAK-954 in Period 2

    Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion

  14. Group E; CLD: Clearance of Dialysate for TAK-954 in Period 2

    Time frame: Day 1 pre-infusion and at multiple time points (up to 4 hours) post-infusion

07

Results

Posted Aug 25, 2020

Participant flow

Participants took part in the study at 4 investigative sites in Czech Republic and Hungary from 21 November 2017 to 09 August 2019.

Participant flow — Overall Study
MilestoneGroup A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring DialysisGroup E: ESRD Requiring Dialysis
Started8897
Completed8897
Not completed0000

Outcome measures

PrimaryGroups A, C and D; Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free)
Time frame:
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Groups A, C and D; Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free)
nanogram per milliliter (ng/mL)Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring Dialysis
TAK-954 (Total)2.623 ± 12.82.536 ± 23.22.660 ± 17.6
TAK-954 (Free)0.1270 ± 29.20.1282 ± 22.50.1572 ± 21.7
Statistical analysis
  • Group A: Healthy Participants vs Group C: Moderate Renal Impairment · ANOVA · p = 0.7265
  • Group A: Healthy Participants vs Group D: Severe Renal Impairment Not Requiring Dialysis · ANOVA · p = 0.9839
  • Group A: Healthy Participants vs Group C: Moderate Renal Impairment · ANOVA · p = 0.9393
  • Group A: Healthy Participants vs Group D: Severe Renal Impairment Not Requiring Dialysis · ANOVA · p = 0.1321
PrimaryGroups A, C and D; AUC(0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Post-dose for TAK-954 (Free and Total)
Time frame:
Day 1 pre-infusion and at multiple time points (up to 72 hours) post-infusion
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Groups A, C and D; AUC(0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Post-dose for TAK-954 (Free and Total)
hour*nanogram per milliliter (h*ng/mL)Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring Dialysis
TAK-954 (Total)22.25 ± 19.124.91 ± 22.928.62 ± 18.1
TAK-954 (Free)1.078 ± 25.71.259 ± 25.11.690 ± 25.9
Statistical analysis
  • Group A: Healthy Participants vs Group C: Moderate Renal Impairment · ANOVA · p = 0.3600
  • Group A: Healthy Participants vs Group D: Severe Renal Impairment Not Requiring Dialysis · ANOVA · p = 0.0816
  • Group A: Healthy Participants vs Group C: Moderate Renal Impairment · ANOVA · p = 0.2686
  • Group A: Healthy Participants vs Group D: Severe Renal Impairment Not Requiring Dialysis · ANOVA · p = 0.0059
PrimaryGroups A, C and D; AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 (Free and Total)
Time frame:
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
Reported as:
Geometric mean · h*ng/mL
Groups A, C and D; AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 (Free and Total)
h*ng/mLGroup A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring Dialysis
TAK-954 (Total)24.39 ± 17.730.00 ± 20.034.28 ± 19.3
TAK-954 (Free)1.184 ± 26.81.516 ± 24.32.025 ± 26.7
Statistical analysis
  • Group A: Healthy Participants vs Group C: Moderate Renal Impairment · ANOVA · p = 0.0998
  • Group A: Healthy Participants vs Group D: Severe Renal Impairment Not Requiring Dialysis · ANOVA · p = 0.0155
  • Group A: Healthy Participants vs Group C: Moderate Renal Impairment · ANOVA · p = 0.0916
  • Group A: Healthy Participants vs Group D: Severe Renal Impairment Not Requiring Dialysis · ANOVA · p = 0.0014
PrimaryGroups A, C and D; AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 (Free and Total)
Time frame:
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
Reported as:
Geometric mean · h*ng/mL
Groups A, C and D; AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 (Free and Total)
h*ng/mLGroup A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring Dialysis
TAK-954 (Total)25.43 ± 16.834.90 ± 16.238.59 ± 23.9
TAK-954 (Free)1.234 ± 28.41.749 ± 24.82.320 ± 29.7
Statistical analysis
  • Group A: Healthy Participants vs Group C: Moderate Renal Impairment · ANOVA · p = 0.0038
  • Group A: Healthy Participants vs Group D: Severe Renal Impairment Not Requiring Dialysis · ANOVA · p = 0.0004
  • Group A: Healthy Participants vs Group C: Moderate Renal Impairment · ANOVA · p = 0.0389
  • Group A: Healthy Participants vs Group D: Severe Renal Impairment Not Requiring Dialysis · ANOVA · p = 0.0011
PrimaryGroups A, C and D; Ae: Amount of TAK-954 Excreted in Urine
Time frame:
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Reported as:
Geometric mean · milligram (mg)
Groups A, C and D; Ae: Amount of TAK-954 Excreted in Urine
milligram (mg)Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring Dialysis
Groups A, C and D; Ae: Amount of TAK-954 Excreted in Urine0.03797 ± 0.0116330.01763 ± 0.00877130.01190 ± 0.0091124
PrimaryGroup E; Ae: Amount of TAK-954 Excreted in Urine in Period 1
Time frame:
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Reported as:
Geometric mean · mg
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 1
mgGroup E: ESRD Requiring Dialysis
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 10.0003489 ± 0.00021788
PrimaryGroup E; Ae: Amount of TAK-954 Excreted in Urine in Period 2
Time frame:
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Reported as:
Geometric mean · mg
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 2
mgGroup E: ESRD Requiring Dialysis
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 20.001240 ± 0.00062000
PrimaryGroups A, C and D; Fe: Fraction of TAK-954 Excreted in Urine
Time frame:
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Reported as:
Geometric mean · percentage of TAK-954 dose
Groups A, C and D; Fe: Fraction of TAK-954 Excreted in Urine
percentage of TAK-954 doseGroup A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring Dialysis
Groups A, C and D; Fe: Fraction of TAK-954 Excreted in Urine19.00 ± 5.80758.808 ± 4.37465.953 ± 4.5595
PrimaryGroup E; Fe: Fraction of TAK-954 Excreted in Urine in Period 1
Time frame:
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Reported as:
Geometric mean · percentage of TAK-954 dose
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 1
percentage of TAK-954 doseGroup E: ESRD Requiring Dialysis
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 10.1739 ± 0.10869
PrimaryGroup E; Fe: Fraction of TAK-954 Excreted in Urine in Period 2
Time frame:
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Reported as:
Geometric mean · percentage of TAK-954 dose
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 2
percentage of TAK-954 doseGroup E: ESRD Requiring Dialysis
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 20.6190 ± 0.30950
PrimaryGroups A, C and D; CLR: Renal Clearance for TAK-954
Time frame:
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Reported as:
Geometric mean · liter per hour (L/h)
Groups A, C and D; CLR: Renal Clearance for TAK-954
liter per hour (L/h)Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring Dialysis
Groups A, C and D; CLR: Renal Clearance for TAK-9542.629 ± 0.787621.255 ± 0.514780.6836 ± 0.56141
PrimaryGroup E; CLR: Renal Clearance for TAK-954 in Period 1
Time frame:
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Reported as:
Geometric mean · L/h
Group E; CLR: Renal Clearance for TAK-954 in Period 1
L/hGroup E: ESRD Requiring Dialysis
Group E; CLR: Renal Clearance for TAK-954 in Period 10.03192 ± 0.017670
PrimaryGroup E; CLR: Renal Clearance for TAK-954 in Period 2
Time frame:
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Reported as:
Geometric mean · L/h
Group E; CLR: Renal Clearance for TAK-954 in Period 2
L/hGroup E: ESRD Requiring Dialysis
Group E; CLR: Renal Clearance for TAK-954 in Period 20.08330 ± 0.041650
PrimaryGroup E; CLD: Clearance of Dialysate for TAK-954 in Period 2
Time frame:
Day 1 pre-infusion and at multiple time points (up to 4 hours) post-infusion
Reported as:
Geometric mean · L/h
Group E; CLD: Clearance of Dialysate for TAK-954 in Period 2
L/hGroup E: ESRD Requiring Dialysis
Group E; CLD: Clearance of Dialysate for TAK-954 in Period 21.368 ± 30.0

Adverse events

Collected over Treatment emergent adverse events (TEAEs) are adverse events that started after the first dose of study drug and no more than 14 days after the last dose of study drug as Treatment 2 (up to Day 29) in Group A, C, and E), and Treatment 1 (up to Day 15) in for Group D. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: Healthy Participants0/8 (0%)0/8 (0%)1/8 (12.5%)
Group C: Moderate Renal Impairment0/8 (0%)0/8 (0%)2/8 (25%)
Group D: Severe Renal Impairment Not Requiring Dialysis0/9 (0%)0/9 (0%)2/9 (22.2%)
Group E: ESRD 1 Hour After Dialysis0/7 (0%)0/7 (0%)1/7 (14.3%)
Group E: ESRD 2 Hours Before Dialysis0/7 (0%)0/7 (0%)2/7 (28.6%)
Most frequent other events
Most frequent other events
EventGroup A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring DialysisGroup E: ESRD 1 Hour After DialysisGroup E: ESRD 2 Hours Before Dialysis
DiarrhoeaGastrointestinal disorders1/81/82/91/72/7
HeadacheNervous system disorders1/81/80/90/70/7
Depressed level of consciousnessNervous system disorders0/81/80/90/70/7

Baseline characteristics

The safety set consisted of all participants who were enrolled and received at least 1 dose of trial drug.

Age, Continuous
Age, Continuous(years)Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring DialysisGroup E: ESRD Requiring DialysisTotal
Mean57.0 ± 15.6270.6 ± 3.5062.2 ± 11.0352.6 ± 10.0660.9 ± 12.38
Sex: Female, Male
Sex: Female, Male(Participants)Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring DialysisGroup E: ESRD Requiring DialysisTotal
Female344011
Male545721
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring DialysisGroup E: ESRD Requiring DialysisTotal
Hispanic or Latino00000
Not Hispanic or Latino889732
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring DialysisGroup E: ESRD Requiring DialysisTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White889732
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring DialysisGroup E: ESRD Requiring DialysisTotal
Czech Republic665320
Hungary224412
Weight
Weight(kilogram (kg))Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring DialysisGroup E: ESRD Requiring DialysisTotal
Mean79.95 ± 7.77375.95 ± 13.03576.22 ± 14.45782.39 ± 7.00678.43 ± 11.072
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring DialysisGroup E: ESRD Requiring DialysisTotal
Mean26.88 ± 4.05126.25 ± 4.16627.33 ± 4.27228.14 ± 2.67327.13 ± 3.765
Height
Height(centimeter (cm))Group A: Healthy ParticipantsGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment Not Requiring DialysisGroup E: ESRD Requiring DialysisTotal
Mean173.25 ± 9.706170.25 ± 9.543166.89 ± 9.519171.00 ± 6.976170.22 ± 8.965

2 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • PRA CZ, s.r.o
    Praha 7, Praha 170 00, Czechia
  • Fakultni Nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • PRA Magyarorszag Kft.
    Budapest, 1077, Hungary
  • Szent Imre Egyetemi Oktatokorhaz Belgyogyazati Szakmak Matrix Intezet
    Budapest, 1115, Hungary
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Aug 2019, 20 months.

Results were first posted in Aug 2020, 1 year after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 20 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2017
First posted
Sep 28, 2017
StartActual
Nov 21, 2017
Primary completionActual
Aug 9, 2019
CompletionActual
Aug 9, 2019
Results first posted
Aug 25, 2020
Last update
Aug 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03296787
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 28, 2017
Start date
Nov 21, 2017
Primary completion
Aug 9, 2019
Completion
Aug 9, 2019
Results posted
Aug 25, 2020
Last update
Aug 25, 2020

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Td-8954

Start the discussion